Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

Lancet Oncol. 2018 May;19(5):591-592. doi: 10.1016/S1470-2045(18)30249-3. Epub 2018 Apr 3.

Authors

Colin D Weekes¹, Jeffrey W Clark¹, Andrew X Zhu²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA. Electronic address: azhu@mgh.harvard.edu.

PMID: 29625880
DOI: 10.1016/S1470-2045(18)30249-3

No abstract available

Publication types

Comment

MeSH terms

Adult
Carcinoma, Hepatocellular*
Humans
Liver Neoplasms*
Pyrrolidinones
Quinolines*

Substances

ARQ 197
Pyrrolidinones
Quinolines